Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Slides:



Advertisements
Similar presentations
Su K. Metcalfe, MD, MPH, Michael T
Advertisements

Volume 155, Issue 3, Pages (March 1996)
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.
Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study  Thomas.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,
Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer
Electronic Updates for JTO Readers
Hedgehog Signaling Pathway and Lung Cancer
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.
A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer  W Jeffrey Petty, MD, Sommer N.
Frank Detterbeck, MD  Journal of Thoracic Oncology 
Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430  Thomas E.
A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.
Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British Columbia  Caroline Mariano, MD, Diana N. Ionescu, MD, Winson.
Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.
An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.
Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer  Masahiko Harada,
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors  Benny Weksler, MD, Anthony Holden, MD, Jennifer.
Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database  Laura C. Caprario, MD, MS,
Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small- Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of.
Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance) 
Randomized Phase II Study of Palifermin for Reducing Dysphagia in Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Unresectable Non-small.
Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 
Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD 
Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy  Todd.
Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E
PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?  Steven G. Gray, PhD  Journal of Thoracic.
A Randomized Phase II Trial of Two Schedules of Docetaxel in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung Cancer  Rogerio.
Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)  Gregory A. Otterson,
Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care  Richard F. Riedel, MD, Xiaofei Wang, PhD, Meg McCormack, PA-C, Eric Toloza,
Should Patient-Rated Performance Status Affect Treatment Decisions in Advanced Lung Cancer?  Esther Dajczman, RN, MScA, Goulnar Kasymjanova, MD, PhD,
Long-Term Results of Radiofrequency Ablation Treatment of Stage I Non-small Cell Lung Cancer: A Prospective Intention-to-Treat Study  Marcello Carlo Ambrogi,
DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.
It’s All in the “Swerve of the Curve”
Phase II Trial of Paclitaxel–Topotecan–Etoposide Followed by Consolidation Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer: CALGB 30002  Antonius.
Pulmonary Resection for Metastases from Colorectal Cancer
International Thymic Malignancies Interest Group: A Way Forward
A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104  Ramaswamy Govindan, MD, Xiaofei.
European Lung Cancer Conference (ELCC) 2016 Organisation
Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer  Alessandro Brunelli, MD, Michele.
Phase I/II Study of Vinorelbine and Exisulind as First-Line Treatment of Advanced Non- small Cell Lung Cancer in Patients at Least 70 Years Old: A Wisconsin.
A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.
Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia.
Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern.
APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28
Temporal Trends in Long-Term Survival and Cure Rates in Esophageal Cancer: A SEER Database Analysis  Attila Dubecz, MD, Isabell Gall, MD, Norbert Solymosi,
Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer  James B. Yu, MD, Roy H. Decker, MD, PhD,
A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.
Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A
Debby P. M. van den Bogaert, MD, Ellen M
Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients  Barbara S. van der Meij,
Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013  Chris Dickhoff, MD, Max Dahele, MBChB., PhD,
A Review of First-Line Treatment for Small-cell Lung Cancer
Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD 
Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W
Presentation transcript:

Definitive Treatment of Poor-Risk Patients with Stage I Lung Cancer: A Single Institution Experience  Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J. Kohman, MD, Elisabeth Dexter, MD, Ernest M. Scalzetti, MD, Jeffrey A. Bogart, MD  Journal of Thoracic Oncology  Volume 4, Issue 1, Pages 69-73 (January 2009) DOI: 10.1097/JTO.0b013e3181914d3a Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Kaplan-Meier estimate of overall survival. Journal of Thoracic Oncology 2009 4, 69-73DOI: (10.1097/JTO.0b013e3181914d3a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Kaplan-Meier estimate of survival by treatment group. Journal of Thoracic Oncology 2009 4, 69-73DOI: (10.1097/JTO.0b013e3181914d3a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Kaplan-Meier estimate of progression free survival. Journal of Thoracic Oncology 2009 4, 69-73DOI: (10.1097/JTO.0b013e3181914d3a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.